Background: Butyrate exerts anti-inflammatory effects in experimental colitis and in lamina propria mononuclear cells of patients with Crohn's disease. Aims: To assess the safety and efficacy of butyrate in Crohn's disease. Patients: Thirteen patients with mild to moderate Crohn's disease were treated with enteric-release sodium butyrate tablets at a dosage of 4 g/day for eight weeks. Methods: Before and after treatment, patients underwent coloscopy with evaluation of the clinical activity of their disease, systemic inflammation index and mucosal expression of interleukin (IL)-1β, IL-6, IL-12, interferon (IFN)-γ, tumour necrosis factor (TNF)-α and nuclear factor (NF)-κB. Results: Of the nine patients (69%) responding to treatment, 7 (53%) exhibited complete response and 2 exhibited partial response. Endoscopic and histological evaluation scores were significantly improved (p <0.05) and significant reductions were seen after treatment in white cell count, erythrocyte sedimentation rate (ESR), mucosal concentrations of NF-κB and IL-1β (p <0.05). Conclusions: Oral administration of butyrate may be effective in inducing clinical improvement or remission in patients with Crohn's disease.
- Crohn's disease
ASJC Scopus subject areas